Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.
Jérôme Contamine, Sanofi's CFO for nearly a decade, plans to step down later this year after a transition period.
Ahead of what’s sure to be a big week for struggling Shire, a prominent investor group is rehashing complaints over the company’s executive pay policy.
Novo Nordisk has teamed up on a project that rewards diabetes patients with lower copays if they stick with their meds.
Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.
After one false alarm, Rigel Pharmaceuticals has officially won FDA approval for its lead rare disease therapy, Tavalisse.
Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.
Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.
Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.
Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice.
